Cargando…

Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events

PURPOSE: Biological therapies are currently the mainstay in the treatment of patients with inflammatory bowel diseases (IBD). Several factors are known to influence the efficacy and tolerability of biologicals, such as CRP levels or previous biological use. Whether patient sex affects the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lie, Mitchell R. K. L., Paulides, Emma, van der Woude, C. Janneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340671/ https://www.ncbi.nlm.nih.gov/pubmed/32592091 http://dx.doi.org/10.1007/s00384-020-03663-2

Ejemplares similares

Inflammatory bowel disease negatively impacts household and family life
por: Paulides, Emma, et al.
Publicado: (2021)

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022)

Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease
por: Paulides, Emma, et al.
Publicado: (2021)

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease
por: Vogelaar, Lauran, et al.
Publicado: (2009)

A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models
por: van der Giessen, Janine, et al.
Publicado: (2019)

Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
por: Sleutjes, Jasmijn A. M., et al.
Publicado: (2021)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
por: Lie, Mitchell R. K. L., et al.
Publicado: (2018)

The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review
por: Paulides, Emma, et al.
Publicado: (2020)

Modulatory Effects of Pregnancy on Inflammatory Bowel Disease
por: van der Giessen, Janine, et al.
Publicado: (2019)

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2021)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
por: Pauwels, Renske W. M., et al.
Publicado: (2020)

Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review
por: Jain, Avni, et al.
Publicado: (2019)

Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters
por: Vogelaar, Lauran, et al.
Publicado: (2017)

Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study
por: van den Brink, Gertrude, et al.
Publicado: (2019)

Comment on: Incidence of Adverse Psychiatric Events During the Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review
por: Salwen-Deremer, Jessica K, et al.
Publicado: (2019)

Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2023)

Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation
por: Sleutjes, Jasmijn A M, et al.
Publicado: (2022)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Does the inflammatory potential of diet affect disease activity in patients with inflammatory bowel disease?
por: Mirmiran, Parvin, et al.
Publicado: (2019)

Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
por: Chun, Ji Young, et al.
Publicado: (2013)

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Pregnane X receptor activation constrains mucosal NF-κB activity in active inflammatory bowel disease
por: Deuring, J. Jasper, et al.
Publicado: (2019)

T.06.3 DOES SARS-COV-2 VACCINATION AFFECT THE COURSE OF INFLAMMATORY BOWEL DISEASE IN PATIENTS ON BIOLOGICAL THERAPY?
por: De Blasio, F., et al.
Publicado: (2022)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events
por: Yu, Yue, et al.
Publicado: (2016)

Drug-Related Adverse Events Necessitating Treatment Discontinuation in Pediatric Inflammatory Bowel Disease Patients
por: Salzmann, Medea, et al.
Publicado: (2022)

Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Ket, Shara Nguyen, et al.
Publicado: (2015)

Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2016)

Endoscopic molecular imaging in inflammatory bowel disease
por: Ham, Nam Seok, et al.
Publicado: (2021)

New endoscopic tools in inflammatory bowel disease
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Endoscopic Evaluation of Surgically Altered Bowel in Patients with Inflammatory Bowel Diseases
por: Sinh, Preetika, et al.
Publicado: (2015)

Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events
por: Asscher, Vera E. R., et al.
Publicado: (2020)

High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23
por: Dahlerup, Jens Frederik, et al.
Publicado: (2016)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2021)

The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults
por: Shapiro, Janna R., et al.
Publicado: (2023)

The intersection of biological sex and gender in adverse events following seasonal influenza vaccination in older adults
por: Shapiro, Janna R., et al.
Publicado: (2023)

Does Drinking Coffee and Tea Affect Bone Metabolism in Patients with Inflammatory Bowel Diseases?
por: Ratajczak, Alicja Ewa, et al.
Publicado: (2021)

Does patient–surgeon sex discordance impact adverse events following primary total hip arthroplasty?
por: FELLÄNDER-TSAI, Li, et al.
Publicado: (2023)

Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice
por: Pauwels, Renske Wilhelmina Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c4gvi3ca7pr9btat5uso75rrmf